BRPI0417605A - derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina - Google Patents
derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocinaInfo
- Publication number
- BRPI0417605A BRPI0417605A BRPI0417605-7A BRPI0417605A BRPI0417605A BR PI0417605 A BRPI0417605 A BR PI0417605A BR PI0417605 A BRPI0417605 A BR PI0417605A BR PI0417605 A BRPI0417605 A BR PI0417605A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor modulators
- chemokine receptor
- chemokine
- ccr2
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53127003P | 2003-12-18 | 2003-12-18 | |
US60/531.270 | 2003-12-18 | ||
PCT/US2004/042321 WO2005060665A2 (en) | 2003-12-18 | 2004-12-16 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0417605A true BRPI0417605A (pt) | 2007-03-27 |
BRPI0417605B1 BRPI0417605B1 (pt) | 2020-05-12 |
BRPI0417605B8 BRPI0417605B8 (pt) | 2021-05-25 |
Family
ID=34710216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417605A BRPI0417605B8 (pt) | 2003-12-18 | 2004-12-16 | n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende. |
Country Status (28)
Country | Link |
---|---|
US (5) | US7576089B2 (pt) |
EP (1) | EP1696919B1 (pt) |
JP (1) | JP4740151B2 (pt) |
KR (2) | KR100859027B1 (pt) |
CN (2) | CN1893945A (pt) |
AP (1) | AP2439A (pt) |
AU (1) | AU2004305079B2 (pt) |
BR (1) | BRPI0417605B8 (pt) |
CA (1) | CA2550596C (pt) |
CR (1) | CR8455A (pt) |
DK (1) | DK1696919T3 (pt) |
EA (1) | EA013631B1 (pt) |
EC (1) | ECSP066615A (pt) |
ES (1) | ES2439894T3 (pt) |
GE (1) | GEP20084505B (pt) |
HK (1) | HK1166321A1 (pt) |
IL (1) | IL175953A (pt) |
IS (1) | IS2956B (pt) |
MA (1) | MA28391B1 (pt) |
MX (1) | MXPA06007000A (pt) |
NI (1) | NI200600136A (pt) |
NO (1) | NO336486B1 (pt) |
NZ (1) | NZ547316A (pt) |
OA (1) | OA13338A (pt) |
TN (1) | TNSN06188A1 (pt) |
UA (1) | UA82917C2 (pt) |
WO (1) | WO2005060665A2 (pt) |
ZA (1) | ZA200604875B (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
JP4948395B2 (ja) * | 2004-04-13 | 2012-06-06 | インサイト・コーポレイション | ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体 |
GEP20084519B (en) | 2004-05-11 | 2008-10-27 | Incyte Corp | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors |
AU2005259983B2 (en) | 2004-06-28 | 2011-07-28 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
JP4116670B2 (ja) | 2004-06-28 | 2008-07-09 | インサイト コーポレイション | ケモカイン受容体の調節剤としての3−アミノシクロペンタンカルボキサミド |
BRPI0513953A (pt) * | 2004-07-30 | 2008-05-20 | Pfizer Prod Inc | métodos para tratamento de doenças ou distúrbios mediados pela ccr2 |
JP2008512463A (ja) * | 2004-09-08 | 2008-04-24 | ボーイズ タウン ナショナル リサーチ ホスピタル | マトリックスメタロプロテイナーゼ−12に関連する糸球体基底膜疾患の治療 |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
WO2006034440A2 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
CN101084212A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途 |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
US7592343B2 (en) | 2004-09-20 | 2009-09-22 | Xenon Pharmaceuticals Inc. | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors |
MX2007003321A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
US8937184B2 (en) * | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007143600A2 (en) | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
US8754107B2 (en) * | 2006-11-17 | 2014-06-17 | Abbvie Inc. | Aminopyrrolidines as chemokine receptor antagonists |
AR065369A1 (es) * | 2007-02-19 | 2009-06-03 | Novartis Ag | Derivados de ciclohexil - amida del acido aril- carboxilico |
CA2687931C (en) * | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
US7977358B2 (en) * | 2007-07-26 | 2011-07-12 | Hoffmann-La Roche Inc. | Pyrazol derivatives |
KR20100087291A (ko) * | 2007-09-25 | 2010-08-04 | 아보트 러보러터리즈 | 케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물 |
EP2297137A1 (en) * | 2008-06-18 | 2011-03-23 | F. Hoffmann-La Roche AG | Novel heteroaryl carboxamide derivatives |
WO2010003240A1 (en) | 2008-07-08 | 2010-01-14 | The Royal Institution For The Advancement Of Learning/Mcgill University | Gmcsf and truncated ccl2 conjugates and methods and uses thereof |
SI2370442T1 (sl) * | 2008-11-26 | 2013-06-28 | Pfizer Inc. | 3-aminociklopentankarboksiamidi kot modulatorji kemokinskega receptorja |
ES2555004T3 (es) | 2008-12-10 | 2015-12-28 | Janssen Pharmaceutica N.V. | Antagonistas 4-azetidinil-1-heteroaril ciclohexanol de CCR2 |
PE20120061A1 (es) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | Derivados de pirimidina como antagonistas del receptor ccr2 |
CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
KR101151415B1 (ko) * | 2009-07-10 | 2012-06-01 | 양지화학 주식회사 | Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 |
PT3091012T (pt) | 2009-12-17 | 2018-06-27 | Centrexion Therapeutics Corp | Antagonistas do receptor ccr2 e suas utilizações |
JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体アンタゴニスト |
EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
KR101743280B1 (ko) | 2010-06-17 | 2017-06-02 | 얀센 파마슈티카 엔.브이. | Ccr2의 사이클로헥실-아제티디닐 길항제 |
WO2012007500A2 (de) | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
JP5868418B2 (ja) * | 2010-12-01 | 2016-02-24 | ヤンセン ファーマシューティカ エヌ.ベー. | Ccr2の4−置換シクロヘキシルアミノ−4−ピペリジニル−アセトアミドアンタゴニスト |
WO2012114223A1 (en) * | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なccr2拮抗薬 |
MX2017017177A (es) | 2015-07-02 | 2018-11-09 | Centrexion Therapeutics Corp | Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona. |
EP3490873A1 (en) * | 2016-08-01 | 2019-06-05 | All Day Designs Ltd | Transportation apparatus |
US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3882145A (en) * | 1972-12-22 | 1975-05-06 | Ppg Industries Inc | Halogenated N-substituted thiocarboxy maleimides |
HU175454B (hu) * | 1977-07-25 | 1980-08-28 | Chinoin Gyogyszer Es Vegyeszet | Sposob poluchenija novykh predel'nykh i chastichno predel'nykh n-acil-pirrol-2,5-dionov |
DE4029054A1 (de) * | 1990-09-13 | 1992-03-19 | Bayer Ag | N-acylpyrrolidin-derivate |
US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
EP0914319B1 (en) | 1996-05-20 | 2001-11-21 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
KR100622613B1 (ko) | 1997-11-18 | 2006-09-11 | 데이진 화-마 가부시키가이샤 | 시클릭 아민 유도체 및 그 약제로서의 용도 |
US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU3389300A (en) * | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
AU3386700A (en) * | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
AU4796700A (en) | 1999-05-13 | 2000-12-05 | Dupont Pharmaceuticals Research Laboratories, Inc. | Ureido-substituted cyclic amine derivatives and their use as drug |
WO2000069432A1 (fr) | 1999-05-18 | 2000-11-23 | Teijin Limited | Moyens de traitement et de prevention contre les maladies associees a des chimiokines |
AU5600100A (en) * | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
US7576117B1 (en) | 1999-08-04 | 2009-08-18 | Teijin Limited | Cyclic amine CCR3 antagonist |
US6410566B1 (en) * | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
JP4029960B2 (ja) * | 2001-10-05 | 2008-01-09 | 独立行政法人理化学研究所 | アブシジン酸生合成阻害剤 |
TWI262077B (en) | 2002-04-29 | 2006-09-21 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
AU2003223755B2 (en) * | 2002-04-29 | 2008-08-21 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
NZ536477A (en) | 2002-04-29 | 2005-05-27 | Merck & Co Inc | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
WO2004042351A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
AU2003284984B2 (en) | 2002-10-30 | 2008-10-23 | Merck Sharp & Dohme Corp. | Gamma-aminoamide modulators of chemokine receptor activity |
EP1558243A4 (en) | 2002-10-30 | 2006-11-02 | Merck & Co Inc | MODULATORS OF ACTIVITY OF TETRAHYDROPYRANYL-CYCLOPENTYL-BENZYLAMIDE-BASED CHEMOKINE RECEPTORS |
WO2004041163A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
JP2006508948A (ja) | 2002-10-30 | 2006-03-16 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性のヘテロアリールピペリジンモジュレーター |
WO2004050024A2 (en) * | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
RU2317295C1 (ru) | 2003-10-27 | 2008-02-20 | Мерк Энд Ко., Инк. | Соль антагониста ccr-2 |
TWI341835B (en) * | 2003-11-12 | 2011-05-11 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
EP1701724A4 (en) | 2004-01-02 | 2007-11-14 | Merck & Co Inc | CYCLOPENTYL AMIDE MODULATORS OF ALKYLAMINO, ARYLAMINO AND SULFONAMIDO OF CHEMOKINE RECEPTOR ACTIVITY |
AU2005206791A1 (en) | 2004-01-20 | 2005-08-04 | Merck Sharp & Dohme Corp. | 2,6-disubstituted piperidines as modulators of chemokine receptor activity |
WO2005072361A2 (en) | 2004-01-28 | 2005-08-11 | Merck & Co., Inc. | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
WO2005110409A2 (en) | 2004-04-26 | 2005-11-24 | Merck & Co., Inc. | Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity |
UY29219A1 (es) * | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
-
2004
- 2004-12-16 US US11/014,322 patent/US7576089B2/en active Active
- 2004-12-16 KR KR1020067012003A patent/KR100859027B1/ko active IP Right Grant
- 2004-12-16 KR KR1020087010051A patent/KR20080052683A/ko not_active Application Discontinuation
- 2004-12-16 AP AP2006003629A patent/AP2439A/xx active
- 2004-12-16 WO PCT/US2004/042321 patent/WO2005060665A2/en active Application Filing
- 2004-12-16 NZ NZ547316A patent/NZ547316A/en not_active IP Right Cessation
- 2004-12-16 CN CNA2004800377375A patent/CN1893945A/zh active Pending
- 2004-12-16 JP JP2006545446A patent/JP4740151B2/ja not_active Expired - Fee Related
- 2004-12-16 MX MXPA06007000A patent/MXPA06007000A/es active IP Right Grant
- 2004-12-16 GE GEAP20049458A patent/GEP20084505B/en unknown
- 2004-12-16 OA OA1200600195A patent/OA13338A/en unknown
- 2004-12-16 CN CN201110207614.3A patent/CN102344398B/zh not_active Expired - Fee Related
- 2004-12-16 BR BRPI0417605A patent/BRPI0417605B8/pt not_active IP Right Cessation
- 2004-12-16 EA EA200600991A patent/EA013631B1/ru not_active IP Right Cessation
- 2004-12-16 DK DK04814497.6T patent/DK1696919T3/da active
- 2004-12-16 AU AU2004305079A patent/AU2004305079B2/en not_active Ceased
- 2004-12-16 UA UAA200606755A patent/UA82917C2/uk unknown
- 2004-12-16 ES ES04814497.6T patent/ES2439894T3/es active Active
- 2004-12-16 CA CA2550596A patent/CA2550596C/en not_active Expired - Fee Related
- 2004-12-16 EP EP04814497.6A patent/EP1696919B1/en active Active
-
2006
- 2006-05-15 IS IS8466A patent/IS2956B/is unknown
- 2006-05-25 IL IL175953A patent/IL175953A/en active IP Right Grant
- 2006-06-07 EC EC2006006615A patent/ECSP066615A/es unknown
- 2006-06-13 ZA ZA200604875A patent/ZA200604875B/xx unknown
- 2006-06-14 CR CR8455A patent/CR8455A/es unknown
- 2006-06-16 MA MA29111A patent/MA28391B1/fr unknown
- 2006-06-16 TN TNP2006000188A patent/TNSN06188A1/fr unknown
- 2006-06-16 NI NI200600136A patent/NI200600136A/es unknown
- 2006-07-13 NO NO20063255A patent/NO336486B1/no not_active IP Right Cessation
-
2008
- 2008-11-19 US US12/274,045 patent/US8697870B2/en not_active Expired - Fee Related
-
2012
- 2012-07-18 HK HK12107037.6A patent/HK1166321A1/xx not_active IP Right Cessation
-
2014
- 2014-02-06 US US14/174,300 patent/US20140155377A1/en not_active Abandoned
-
2015
- 2015-05-06 US US14/705,382 patent/US20150231114A1/en not_active Abandoned
-
2016
- 2016-11-04 US US15/344,327 patent/US20170050942A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0417605A (pt) | derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina | |
BR0316732A (pt) | Derivados de 3-aminopirrolidina como moduladores de receptores de quimiocina | |
BR0312695A (pt) | Derivados de 1h-pirrolidina-2,4-diona espirocìclicos substituìdos por cis-alcóxi | |
BRPI0510409A (pt) | heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase | |
BRPI0510410A (pt) | compostos orgánicos | |
BRPI0413860A (pt) | [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia | |
ECSP055621A (es) | Aza-biciclo-alquil-éteres y su uso como agonistas de alfa7-nachr | |
BRPI0510665A (pt) | 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas | |
BR0214666A (pt) | Derivados de acetileno tendo atividade antagonìstica de mglur5 | |
BR0010304A (pt) | Derivados de piperazina úteis como antagonistas do ccr5 | |
MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
BRPI0513405A (pt) | tienopirimidinas úteis como inibidores de aurora quinase | |
BRPI0517945A (pt) | derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3 | |
BRPI0508644A (pt) | catalisador ácido sólido e método de utilizar o mesmo | |
ATE509920T1 (de) | Quadratsäurederivate als inhibitoren von histondeacetylase | |
BR0214884A (pt) | Derivados de 7-amino-benzotiazol como ligantes do receptor de adenosina | |
ATE485261T1 (de) | Salicylsäurederivate | |
BR0317222A (pt) | Compostos de 2-aminocarbonil-quinolina como antagonistas dos receptores de difosfato de adenisina de plaquetas | |
BR0308592A (pt) | Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5) | |
BR0317459A (pt) | Novos derivados de piperidina como moduladores do receptor ccr5 quimiocina | |
BRPI0411738A (pt) | compostos orgánicos | |
EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
BRPI0412910A (pt) | derivados de nicotinamida úteis como inibidores de pde4 | |
BRPI0108990B8 (pt) | processo para preparação de derivados de pirimidona com atividade antifungos | |
BRPI0412862A (pt) | derivados da nicotinamida úteis como inibidores de pde4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: "PARA: INT. CL. A61K 31/44 Ipc: A61K 31/44 (2011.01), C07D 401/12 (2011.01), C07D Free format text: PARA: INT. CL. A61K 31/44; C07D 401/12, 401/14; A61P 37/00 Ipc: A61K 31/44 (2011.01), C07D 401/12 (2011.01), C07D |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: INCYTE CORPORATION (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2701 DE 11-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |